Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $631.30 | 25 | 74.2% |
| Education | $218.98 | 3 | 25.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $241.90 | 4 | $0 (2020) |
| AbbVie, Inc. | $179.50 | 4 | $0 (2019) |
| Gilead Sciences, Inc. | $164.70 | 2 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $156.36 | 11 | $0 (2019) |
| Melinta Therapeutics, Inc. | $58.42 | 4 | $0 (2019) |
| Allergan Inc. | $25.53 | 2 | $0 (2018) |
| ViiV Healthcare Company | $23.87 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $122.87 | 2 | Astellas Pharma US Inc ($99.00) |
| 2019 | $478.05 | 14 | AbbVie, Inc. ($179.50) |
| 2018 | $249.36 | 12 | Astellas Pharma US Inc ($112.91) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/22/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: HIV | ||||||
| 02/04/2020 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 11/05/2019 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug), PIFELTRO, DELSTRIGO | Food and Beverage | In-kind items and services | $12.77 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/31/2019 | Astellas Pharma US Inc | — | Education | In-kind items and services | $29.99 | General |
| 10/25/2019 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug), PIFELTRO, DELSTRIGO | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/18/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $14.23 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $10.99 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/03/2019 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $73.19 | General |
| Category: HCV | ||||||
| 08/12/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $91.51 | General |
| 07/30/2019 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug), PIFELTRO, DELSTRIGO | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/03/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $114.99 | General |
| Category: Virology | ||||||
| 03/28/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: Virology | ||||||
| 03/22/2019 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $23.94 | General |
| 03/14/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: Virology | ||||||
| 03/08/2019 | Melinta Therapeutics, Inc. | Baxdela (Drug) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: ANTIBIOTICS | ||||||
| 02/22/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $12.83 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/12/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $12.01 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/11/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $89.99 | General |
| 09/01/2018 | Astellas Pharma US Inc | MYCAMINE (Drug), CRESEMBA | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 08/10/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/18/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug), Vabomere, Orbactiv | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 05/11/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug), Vabomere, Orbactiv | Food and Beverage | In-kind items and services | $12.04 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 05/04/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $12.17 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/01/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $12.23 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/27/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 3 | 80 | 121 | $28,181 | $12,448 |
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 31 | 37 | $13,061 | $6,043 | 46.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 29 | 63 | $11,025 | $5,257 | 47.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 20 | 21 | $4,095 | $1,147 | 28.0% |
About Dr. Raymond Coghlan, MD
Dr. Raymond Coghlan, MD is a Infectious Disease healthcare provider based in Shreveport, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285683086.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raymond Coghlan, MD has received a total of $850.28 in payments from pharmaceutical and medical device companies, with $122.87 received in 2020. These payments were reported across 28 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($631.30).
As a Medicare-enrolled provider, Coghlan has provided services to 80 Medicare beneficiaries, totaling 121 services with total Medicare billing of $12,448. Data is available for 1 year (2020–2020), covering 3 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Shreveport, LA
- Active Since 05/09/2006
- Last Updated 11/21/2007
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1285683086
Products in Payments
- Mavyret (Drug) $155.56
- ZERBAXA (Drug) $89.65
- Epclusa (Drug) $73.19
- ISENTRESS (Drug) $66.71
- Baxdela (Drug) $58.42
- AVYCAZ (Drug) $25.53
- DOVATO (Drug) $23.87
- MYCAMINE (Drug) $22.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Shreveport
Guillermo Padilla, M.d, M.D
Infectious Disease — Payments: $186,696
Jihad El-Hayek, M.d, M.D
Infectious Disease — Payments: $13,949
Gerardo Negron, Md, MD
Infectious Disease — Payments: $10,209
Dr. Mohammad Alam, Md, MD
Infectious Disease — Payments: $3,936
John Todd, M.d, M.D
Infectious Disease — Payments: $3,715
John King, M.d, M.D
Infectious Disease — Payments: $63.78